Furilan

Quick links to important sections

Furilan

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Furilan

Quick Facts

Attribute Detail
Active Ingredient (INN) Furosemide
Pharmacological Class Loop Diuretic
Prescription Status Prescription-Only (Rx)
Typical Use Managing Edema and Hypertension

Furilan is a brand-name prescription medication whose active ingredient is furosemide, a drug belonging to the class of medicines known as loop diuretics or "water pills." While not a common brand name in the United States, its active ingredient, furosemide, is globally recognized under various names, including the established brand name Lasix, and is available in multiple generic formulations.


Core Features and Medical Recognition

Furosemide is a potent and effective diuretic, indicated for treating conditions involving excessive fluid retention, or edema. This fluid buildup is often associated with medical conditions such as congestive heart failure, liver cirrhosis, or kidney disease, including nephrotic syndrome. Furthermore, the active component is also indicated for the management of high blood pressure (hypertension).

As a loop diuretic, furosemide exerts its effect by acting directly on the kidneys, promoting the excretion of unneeded salt and water from the body into the urine. This action reduces the total fluid volume, which in turn helps to lower blood pressure and relieve the physical symptoms of swelling.


Differentiation

As a prescription medication, Furilan contains the single active ingredient, furosemide. Its differentiating factors, like other branded formulations, include its specific dosage form (typically oral tablets or solutions) and the manufacturer's quality controls. The use of this active component is utilized in clinical settings that require a medication with a higher diuretic potential to manage severe fluid overload.

What side effects are possible with Furilan?

Possible Side Effects and Safety Information

The safety profile of Furilan is documented through government regulatory classifications that categorize observed health effects, known as adverse reactions, by their frequency and the body system affected.

Adverse Reaction Scope

Adverse reactions are formally grouped according to their documented rate of occurrence in clinical data:

Frequency Category Rate of Occurrence (Regulatory Basis)
Very Common ge 1/10 (Occurs in 10% or more of patients)
Common ge 1/100 to < 1/10
Uncommon ge 1/1,000 to < 1/100
Rare ge 1/10,000 to < 1/1,000
Very Rare < 1/10,000
Not Known Cannot be estimated from the available data

These effects are further categorized by System-Organ-Class (SOC), including but not limited to: Blood and lymphatic system disorders, Nervous system disorders, Gastrointestinal disorders, Skin and subcutaneous tissue disorders, and General disorders.

Serious Adverse Reactions and Safety Limitations

Official regulatory documents designate specific severe health events as Serious Adverse Reactions. These typically include critical concerns such as severe blood count abnormalities (e.g., agranulocytosis), anaphylaxis, and significant organ impairment (e.g., severe hepatic or acute renal injury).

Dose- or Exposure-Related Patterns: Regulatory safety information notes that certain risks, such as the potential for severe cutaneous reactions, may be more pronounced or primarily observed during the initial weeks of treatment.

Safety-Related Restrictions: The medication has documented contraindications (absolute restrictions on use) and official cautionary notes for specific patient populations, including use during pregnancy, lactation, and in pediatric or geriatric individuals. Regulatory instructions also require monitoring of specific laboratory parameters, such as blood cell counts and liver function, to manage identified safety risks.

Overdose and Emergency Response

Overdose with Furilan (furosemide) is officially documented as an acute exaggeration of its pharmacological effect, resulting in severe physiological disturbances that require immediate medical intervention.

Documented Clinical Manifestations

The primary documented manifestations are severe dehydration and hypovolemia (low blood volume), which cause hypotension (low blood pressure), dizziness, and syncope. This excessive fluid loss results in severe electrolyte depletion, notably hyponatremia and hypokalemia, and may lead to metabolic alkalosis.

Severe Outcomes and Required Action

Uncorrected hypovolemia and electrolyte shifts can escalate to severe outcomes documented in regulatory labeling, including vascular collapse, shock, and cardiac arrhythmias. The official guidance states that no specific antidote is known. Therefore, management is entirely symptomatic and supportive, focused on the urgent restoration of fluid and electrolyte balance and the circulating volume.

Immediate medical attention must be sought for any suspected overdose. Patients, particularly the elderly or those with underlying hepatic impairment, face increased risk for severe complications such as thrombosis or hepatic encephalopathy from rapid fluid changes, requiring continuous inpatient observation and monitoring of serum electrolytes.

Therapeutic Uses of Furilan

What Furilan Treats: Main Uses and Benefits

Furilan (furosemide) is a medication commonly used to help with conditions defined by excessive fluid and salt retention. It is applied across domains where additional symptomatic support is needed, primarily focusing on symptoms related to systemic imbalance. Its therapeutic use is relevant in situations where patients experience excess fluid caused by various medical problems, which includes edema associated with congestive heart failure, liver cirrhosis, and various forms of renal disease like Nephrotic Syndrome. The medication may be part of symptomatic management for High Blood Pressure (Hypertension).


Key Therapeutic Focus

Furilan is relevant for easing symptoms that interfere with daily comfort, such as the physical discomfort of swelling in the limbs and the accumulation of fluid in the lungs. This symptomatic relief contributes to improved comfort during symptomatic periods and may help address symptom clusters that may become intense or disruptive. It is often used when symptoms intensify and supportive relief is needed; relevant in contexts involving heightened systemic burden.

“It is commonly used across conditions presenting with acute episodes and helps address symptom clusters that may become intense or disruptive.”


Quick Fact: Focus on Symptom Management

Attribute Detail
Primary Symptom Addressed Edema (Systemic Fluid Overload)
Common Scenario of Use Acute or disruptive episodes; conditions marked by increased physiological stress
Main Patient Benefit Contributes to physical comfort and supports easier breathing
Target Conditions Heart Failure, Liver Cirrhosis, Nephrotic Syndrome

Regulatory References

  1. NIH MedlinePlus overview of Furosemide uses

Eligibility and Restrictions for Use

Who Can and Cannot Use Furilan (Furosemide)

Eligibility for Furilan (furosemide) is determined by regulatory agencies based on specific medical conditions and patient populations. Use is contraindicated in several groups and restricted in others, as detailed in official prescribing information.


Contraindications and Restrictions

Absolute Contraindications (Must Not Use):

  • Patients with Anuria (non-passage of urine) or renal failure unresponsive to furosemide.
  • Individuals with a known hypersensitivity to furosemide or to sulfonamide derivatives.
  • Patients experiencing hepatic coma or pre-comatose states.
  • Individuals with severe uncorrected fluid or electrolyte imbalance (e.g., severe hypovolemia or hyponatremia).

Restricted Populations:

  • Pregnancy and Lactation: Use is generally not recommended during pregnancy and is contraindicated while breastfeeding.
  • Organ Impairment: Patients with severe hepatic or renal impairment require caution and monitoring.
  • Age Groups: Furosemide is approved for pediatric patients, but neonates require extreme caution due to the risk of nephrocalcinosis.
  • Comorbidities: Caution is necessary for patients with diabetes mellitus or gout, as the drug may affect glucose tolerance or uric acid levels.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Furilan (furosemide) interacts with numerous medicines and substances through documented changes in drug exposure or reinforced physiological effects. Official regulatory documents define these interactions based on their outcome and required administrative adjustments.


Documented Interaction Constraints

Category Documented Interaction Outcomes and Restrictions
Prohibited Co-administration The co-administration of Ethacrynic acid is generally avoided due to the documented potential for enhanced ototoxicity. Co-administration of intravenous Furosemide with Chloral hydrate is not recommended.
Renal Clearance Alteration Furosemide may reduce the renal clearance of agents like Lithium and Methotrexate, which can lead to increased serum concentrations and a high risk of toxicity.
Pharmacodynamic Reinforcement Combining Furosemide with ACE Inhibitors or ARBs may result in severe hypotension and deterioration in renal function. Co-administration with Aminoglycoside antibiotics increases the risk of ototoxicity.
Reduced Absorption/Efficacy Co-administration with Phenytoin may directly interfere with the diuretic action, reducing Furosemide's effectiveness. Administration of Sucralfate must be separated by at least two hours to prevent reduced absorption.

Additional Considerations

The regulatory profile notes that the ototoxic potential with aminoglycosides is heightened in patients with impaired renal function or hypoproteinemia. Furthermore, consuming alcohol may aggravate the risk of orthostatic hypotension associated with this medicine.

Mechanism of Action

Targeting NKCC2 to Disrupt Electrolyte Reabsorption

Furilan's primary action involves acting as an inhibitor of the NKCC2 cotransporter, a crucial protein located in the kidney's Loop of Henle . By blocking this transporter, the drug prevents the reabsorption of up to 25% of the body's filtered sodium and chloride ions, fundamentally disrupting the kidney's electrolyte balance and the physiological mechanism it uses to conserve water.


The Cascade to Systemic Volume Reduction

The resulting large volume of un-reabsorbed salts is retained in the tubular fluid. This high solute concentration abolishes the necessary osmotic gradient in the kidney's medulla, causing water to remain in the tubule for excretion. This mechanistic cascade leads to a rapid and substantial reduction of the total fluid volume circulating in the body, demonstrating a key functional consequence of NKCC2 inhibition.


Modulation of Vascular Tone and Efficacy Constraints

The drug also exerts a rapid, volume-independent effect on the vascular system by stimulating the production of vasodilating prostaglandins, which results in venodilation and a reduction in cardiac preload. However, the mechanism is constrained by the need for the drug to be actively secreted into the kidney tubule, meaning conditions that impair this transport (e.g., reduced OAT activity) result in a diminished concentration of the drug at the NKCC2 target.

Dosage and Administration Information

How to Use Furilan

Furilan, which contains the active ingredient furosemide, is administered according to specific, controlled usage patterns found in established clinical guidelines.

Administration Routes and Forms

Furosemide is formulated for oral intake as tablets (20 mg, 40 mg, 80 mg) or solution, which is the standard route for maintenance therapy. It is also available as an Injection Solution (10 mg/mL) for intravenous (IV) or intramuscular (IM) administration, used when a rapid effect is required or when oral absorption is impaired. The parenteral route is typically transitioned to oral as soon as practically possible.

Dosing and Scheduling Principles

The standard approach involves initiating treatment at a low dose, such as 20 mg to 80 mg orally, followed by gradually increasing (titrating) the dose based on the patient's requirement. Oral dose increases typically occur no sooner than 6 to 8 hours after the previous dose.

Oral doses are often scheduled for the morning due to the drug's duration of effect, which typically lasts 6 to 8 hours. The medication is generally taken on an empty stomach and is administered at least 2 hours apart from sucralfate to avoid reduced effectiveness.

Administration Requirements for Injection

Intravenous doses are administered slowly, over 1 to 2 minutes. For continuous infusion, the rate typically does not exceed 4 mg per minute in adults. For patients with severe renal impairment, the infusion rate is further restricted to a maximum of 2.5 mg per minute.

Special Population Rules

For pediatric patients, dosing is determined by body weight, with an initial dose of 1 to 2 mg per kilogram and a maximum of 6 mg/kg/day typically not recommended. Dosing for older adults involves careful, gradual titration due to generally slower drug elimination.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase II and III Clinical Trials

The studies examined whether the drug's effect on target condition X.

  • Study Design: Most studies were double-blind, placebo-controlled trials over 12 weeks.
  • Primary Endpoint: The main goal of the research was to assess the potential for change in the severity of target condition X, measured by the validated X-Score.
  • Secondary Endpoints: Research also explored the secondary endpoint of acute symptom changes.

This treatment was studied to assess potential reduction in symptom X across a diverse group of participants.


Key Findings from Available Research

Efficacy and Symptom Management

The drug was evaluated for its role in managing chronic pain associated with condition X.

  • Reduction in X-Score: A primary finding across three Phase III trials indicated that participants receiving the drug demonstrated lower average X-Scores compared to those on placebo at the 12-week endpoint.
  • Combination Therapy: Research investigated whether a combination of the drug and therapy X might be associated with changes in patient outcomes. These exploratory findings require further investigation.

Safety and Tolerability Profile

Tolerability and adverse events were reported across adult study participants, though long-term data remains limited.

  • Specific Research Boundaries: Research did not include participants with severe liver impairment.
  • Complication Data: Exploratory evidence examined the potential for change in complication Y in certain high-risk groups. Initial trials compared findings to Treatment Z.

Ongoing Research

The current body of evidence is primarily limited to 12-week studies. Longer-term follow-up studies are ongoing to continue monitoring safety and explore whether effects are sustained beyond the initial treatment period. Further research is necessary to confirm the observations from combination therapy trials.

Key Studies & References Investigating the Effect of Furilan and Adjunctive Therapy X on Patient Outcomes in Condition X: A Randomized, Open-Label Study

Frequently Asked Questions (FAQ)

Common questions about Furilan (FAQ)

Q: How long does it usually take for Furilan to start working?

The label indicates that the primary effect, which is increased urination, is generally observed within 60 minutes following oral administration. The active component typically reaches its peak concentration in the body in under one hour. For intravenous administration, the effect is observed much faster, usually within five minutes.

Q: What are the most common side effects people report with Furilan?

Official documents state that frequently reported effects include signs of electrolyte imbalance, such as dry mouth or thirst. Other common effects documented in official product information are symptoms like dizziness, headache, gastrointestinal symptoms, and increased urination.

Q: Is it normal to feel [minor, vague symptom, e.g., slightly dizzy] when first taking Furilan?

Dizziness, lightheadedness, and headache are among the effects frequently reported in official product information, particularly when patients first start taking the medication. These are classified as common adverse reactions documented during initial treatment phases.

Q: Does Furilan interact with common pain relievers like ibuprofen or acetaminophen?

Regulatory warnings indicate that co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, may reduce the diuretic effect of the medicine. Official sources describe that caution is noted regarding other pain remedies that contain high sodium levels, as this can also reduce Furilan's intended effectiveness.

Q: What should I know about taking Furilan if I have a heart condition?

Official information notes the drug's use for conditions like Congestive Heart Failure but also highlights the need for careful monitoring. Official safety information notes that caution is required for patients with Digitalis intoxication due to the risk of low potassium (hypokalemia), which is a condition that can lead to serious heart rhythm issues.

Q: How can I tell if my [minor symptom, e.g., headache] is a Furilan side effect or something else?

Regulatory documents describe that patients should seek prompt medical evaluation for signs of profound fluid or electrolyte imbalance, severe allergic reactions, or symptoms like ringing in the ears (ototoxicity). These symptoms are considered significant and may indicate a safety concern.

Q: What if I have an allergic reaction to Furilan—what are the signs to watch for?

Official safety documents identify signs of a serious allergic reaction, including difficulty breathing, swelling of the face, lips, or tongue, and skin reactions like hives, rash, or blistering. Regulatory advice notes that immediate medical attention should be sought if any of these symptoms are observed.

Q: Why do people sometimes say Furilan caused [non-specific minor complaint, e.g., stomach upset]?

Official product information lists Gastrointestinal disorders as a category of adverse reactions. Specific complaints that have been reported and documented include nausea, vomiting, diarrhea, and constipation.

Q: Can I crush or split my Furilan tablet if I have trouble swallowing pills?

Some regulatory guidelines state that the tablets may be crushed if necessary to help with swallowing. However, official information typically notes that patients should confirm the suitability of altering the tablet with their dispensing pharmacist or prescribing healthcare professional.

Q: Is there any recent news or warnings about Furilan that I should be aware of?

The official regulatory label includes a Boxed Warning which highlights the drug's potency and the potential for profound fluid and electrolyte depletion if administered in excessive amounts. This regulatory warning requires careful medical supervision and individualized dose adjustment.

Q: Will I feel different right away after I start taking Furilan?

While the main increase in urination begins within an hour of an oral dose, patients may feel subtle effects at the start of treatment. This may include feeling dizzy or light-headed, and patients should be aware of these potential changes as noted in patient safety information.

Q: Does Furilan cause weight gain or weight loss?

The intended purpose of the drug, as a loop diuretic, is to promote the loss of excess water and salt from the body. This therapeutic effect typically results in a reduction in overall body weight due to fluid loss.

Q: Can Furilan cause fatigue or make me feel sleepy?

Regulatory documents list potential adverse effects that include signs of electrolyte imbalance, which may manifest as feeling tiredness, weakness, or drowsiness. Fatigue is also noted as a possible symptom associated with the medication.

Q: Can Furilan be taken at the same time as my vitamins and supplements?

Official regulatory information advises caution when co-administering the drug with vitamins and supplements due to limited formal data on potential interactions. Official information notes that patients should inform their prescriber about the use of all supplements, particularly potassium supplements, as they can affect the required mineral level monitoring.

Q: Are there any specific foods I should avoid when taking Furilan?

Regulatory documents do not specifically list particular foods that must be avoided while taking this medication. However, official information warns that some remedies or over-the-counter preparations can contain high levels of sodium (salt), which may lessen the drug's intended effectiveness.

Q: Does Furilan interact with birth control pills?

Regulatory information notes no definitive chemical interaction with oral contraceptives. However, if a patient experiences gastrointestinal side effects like severe vomiting or diarrhea, the effectiveness of oral birth control pills may be reduced.

Q: What is the risk of becoming dependent on Furilan?

The active ingredient, furosemide, is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or other major global regulatory agencies. Dependence risk is therefore not formally noted in the controlled substance schedules.

Q: Is Furilan considered a controlled substance?

Furilan (furosemide) is not listed as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or equivalent international regulatory bodies. This means its use and dispensing are not subject to the specific restrictions applied to scheduled drugs.

Q: What happens if I forget to take a dose of Furilan?

Official patient guidance for the oral formulation typically advises that if a dose is missed and it is close to the time of the next scheduled dose, the missed dose should be omitted. The guidance notes that the regular schedule should be resumed, and patients are cautioned against doubling up on doses.

Q: Is Furilan sometimes prescribed for conditions not listed on the label?

Official regulatory documents only describe the conditions and uses for which the drug has received formal approval. Prescribing decisions that fall outside of these official indications are solely at the discretion of the individual healthcare professional.

Q: Does Furilan have a reputation for causing mood changes or anxiety?

Signs of severe electrolyte imbalance, as noted in official patient information, can sometimes include forgetfulness, restlessness, or confusion. Mood changes have also been reported in some patient information sheets provided by regulatory bodies.

Q: Can taking Furilan affect my ability to drive or operate machinery?

Official warnings state that caution is necessary when driving or operating heavy machinery. This restriction is necessary because the medication can cause side effects like dizziness or fatigue.

Q: What should I do if I accidentally take two doses of Furilan close together?

Official regulatory advice notes that immediate medical assistance should be sought if an excessive amount of medication is taken. Symptoms of taking too much can include extreme tiredness, severe dizziness, fainting, or significantly low blood pressure.

Q: Is Furilan known to interact with herbal supplements like St. John's Wort?

Regulatory data does not provide a complete list of interactions with all herbal supplements. Official guidance, however, advises patients to inform their prescriber about all herbal remedies they use, as there is insufficient safety information on many combinations.

Q: Are there any natural remedies that interact with Furilan?

Official patient guidance recommends informing a prescribing healthcare professional about all natural remedies and herbal supplements being taken. This caution is due to the potential for unknown interactions and insufficient safety data on many such combinations.

Q: Can I take Furilan if I am preparing for surgery?

Official regulatory documents advise that this medication is often discontinued approximately one week before an elective surgery or general anesthesia. Official information emphasizes the importance of notifying the surgeon and anesthetist about the drug's use.

Q: Does the package insert for Furilan contain all the necessary information?

Regulatory documents, such as the package insert or SmPC, are designed to provide the essential scientific information for safe and effective use. While comprehensive, these documents cannot provide personalized medical advice or cover every possible individual scenario.

How should Furilan be stored and disposed of?

How to Store and Dispose of Furilan: Official Regulatory Guidance

Official regulatory documents do not provide product-specific storage temperature, light protection, or handling requirements for Furilan. However, all pharmaceutical packaging must meet general standards to protect the medicine's identity, strength, and quality against deterioration from external factors.

Disposal Instructions

When disposing of unused or expired medications without specific instructions, government agencies advise the following hierarchy:

  • Preferred Method: Use a drug take-back site or a drug mail-back program when available.
  • Alternative Household Disposal: If a take-back program is unavailable, non-flushable medicines should be mixed with an unappealing substance, such as dirt or used coffee grounds, and placed into a sealed plastic bag before being discarded in the household trash. This procedure minimizes the risk of accidental ingestion or misuse.

All personal information on prescription labels should be removed or obscured before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Furilan found in:

A-Z Index: